Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

<p>– Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden – – 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose entirely free of injections at year 3 […]</p>
<p>The post <a href="https://forextv.com/top-news/adverum-biotechnologies-announces-3-year-efficacy-and-safety-results-from-the-optic-extension-study-in-patients-with-wet-amd-at-aao-2023/">Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>